RT Journal Article
SR Electronic
T1 Persistent symptoms among children and adolescents with and without anti-SARS-CoV-2 antibodies: a population-based serological study in Geneva, Switzerland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.23.21268298
DO 10.1101/2021.12.23.21268298
A1 Dumont, Roxane
A1 Nehme, Mayssam
A1 Lorthe, Elsa
A1 de Mestral, Carlos
A1 Richard, Viviane
A1 Baysson, Hélène
A1 Pennacchio, Francesco
A1 Lamour, Julien
A1 Semaani, Claire
A1 Zaballa, María-Eugenia
A1 Pullen, Nick
A1 Perrin, Anne
A1 L’Huillier, Arnaud G.
A1 Posfay-Barbe, Klara M.
A1 Guessous, Idris
A1 Stringhini, Silvia
A1 on behalf of the Specchio-COVID19 study group
YR 2021
UL http://medrxiv.org/content/early/2021/12/23/2021.12.23.21268298.abstract
AB Background It is now established that a significant proportion of adults experience persistent symptoms after SARS-CoV-2 infection. However, evidence for children and adolescents is still inconclusive. In this population-based study, we examine the proportion of children and adolescents reporting persistent symptoms after SARS-CoV-2 infection, as assessed by serological status, and compare this to a seronegative control group.Methods We conducted a serosurvey in June-July 2021, recruiting 660 children and adolescents from 391 households selected randomly from the Geneva population. We tested participants for anti-SARS-CoV-2 antibodies targeting the nucleocapsid (N) protein to determine previous infection. A parent filled a questionnaire including questions on COVID-19-related symptoms lasting at least 2 weeks.Findings Among children seropositive for anti-SARS-CoV-2 antibodies, the sex- and age-adjusted prevalence of symptoms lasting longer than two weeks was 18.3%, compared to 11.1% among seronegative children (prevalence difference (ΔaPrev)=7.2%, 95%CI:1.5-13.0). Main symptoms declared among seropositive children were fatigue (11.5%) and headache (11.1%). For 8.6% (aPrev, 95%CI: 4.7-12.5) of seropositives, these symptoms were declared to be highly limiting of daily activities. Adolescents aged 12-17 years had a higher adjusted prevalence of persistent symptoms (aPrev=29.1%, 95%CI:19.4-38.7) than younger children. Comparing seropositive and seronegative adolescents, the estimated prevalence of symptoms lasting over four weeks is 4.4% (ΔaPrev, 95%CI:-3.8-13.6).Interpretation A significant proportion of children aged 12 to 17 years had symptoms lasting over two weeks after SARS-CoV-2 infection, with an estimated prevalence of symptoms lasting over 4 weeks of 4.4% in this age group. This represents a large number of adolescents in absolute terms, and should raise concern in the context of unknown long-term evolution of symptoms. Younger children appear to experience long-lasting symptoms less frequently, as no difference was observed between the seropositive and seronegative sample. Further studies with larger samples sizes are needed.Funding Swiss Federal Office of Public Health, Geneva General Directorate of Health, HUG Private Foundation, SSPH+, Fondation des Grangettes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSwiss Federal Office of Public Health, Geneva General Directorate of Health, HUG Private Foundation, Swiss School of Public Health, Fondation des Grangettes.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Specchio-COVID19 study was approved by the Cantonal Research Ethics Commission of Geneva, Switzerland (CCER Project ID 2020-00881).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data are accessible to researchers upon reasonable request for data sharing to the corresponding author.ΔaPrevadjusted Prevalence DifferenceaPrevadjusted PrevalenceaPRadjusted Prevalence RatioCIConfidence intervalCOVID-19Coronavirus disease 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2